JP6374959B2 - Ｄｎａ−ｐｋ阻害剤 - Google Patents
Ｄｎａ−ｐｋ阻害剤 Download PDFInfo
- Publication number
- JP6374959B2 JP6374959B2 JP2016523925A JP2016523925A JP6374959B2 JP 6374959 B2 JP6374959 B2 JP 6374959B2 JP 2016523925 A JP2016523925 A JP 2016523925A JP 2016523925 A JP2016523925 A JP 2016523925A JP 6374959 B2 JP6374959 B2 JP 6374959B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- mmol
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1cnc(*)cc1 Chemical compound Cc1cnc(*)cc1 0.000 description 20
- AKPUZJOEQGBKPY-HSHIGALWSA-N C/C=N\C=C(\C)/C=C Chemical compound C/C=N\C=C(\C)/C=C AKPUZJOEQGBKPY-HSHIGALWSA-N 0.000 description 1
- HPZXEWQLFFUHHD-UHFFFAOYSA-N CC(COc1ccccc1Br)=C Chemical compound CC(COc1ccccc1Br)=C HPZXEWQLFFUHHD-UHFFFAOYSA-N 0.000 description 1
- SGYAHQJEQHTWHR-VOTSOKGWSA-N CC1(C)c2cccc(/C=C/[N+]([O-])=O)c2OC1 Chemical compound CC1(C)c2cccc(/C=C/[N+]([O-])=O)c2OC1 SGYAHQJEQHTWHR-VOTSOKGWSA-N 0.000 description 1
- HNCLOAJZDAMBQR-UHFFFAOYSA-N CC1(C)c2cccc(C=O)c2OC1 Chemical compound CC1(C)c2cccc(C=O)c2OC1 HNCLOAJZDAMBQR-UHFFFAOYSA-N 0.000 description 1
- FHRIFPIEZKZPBE-UHFFFAOYSA-N CC1(C)c2cccc(CCN)c2OC1 Chemical compound CC1(C)c2cccc(CCN)c2OC1 FHRIFPIEZKZPBE-UHFFFAOYSA-N 0.000 description 1
- SNOPQSLWDMEXLN-UHFFFAOYSA-N CC1(C)c2cccc(CCNc3cc(-c4ccc(N5CCN(C)CC5)nc4)ncn3)c2OC1 Chemical compound CC1(C)c2cccc(CCNc3cc(-c4ccc(N5CCN(C)CC5)nc4)ncn3)c2OC1 SNOPQSLWDMEXLN-UHFFFAOYSA-N 0.000 description 1
- MNUVJIPQYZJXAV-UHFFFAOYSA-N CC1(C)c2cccc(CCNc3cc(Cl)ncn3)c2OC1 Chemical compound CC1(C)c2cccc(CCNc3cc(Cl)ncn3)c2OC1 MNUVJIPQYZJXAV-UHFFFAOYSA-N 0.000 description 1
- BEIGEFOVGRASOO-UHFFFAOYSA-N CC1(C)c2ccccc2OC1 Chemical compound CC1(C)c2ccccc2OC1 BEIGEFOVGRASOO-UHFFFAOYSA-N 0.000 description 1
- XOGDXTACOCVNOT-UHFFFAOYSA-N CC1(C23C)C=NC2=CC(C)=CC=C3N=C1 Chemical compound CC1(C23C)C=NC2=CC(C)=CC=C3N=C1 XOGDXTACOCVNOT-UHFFFAOYSA-N 0.000 description 1
- MVTHDBVIVSNEHZ-UHFFFAOYSA-N Cc(cc1N=C)ccc1SC Chemical compound Cc(cc1N=C)ccc1SC MVTHDBVIVSNEHZ-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N Clc1cc(Cl)ncn1 Chemical compound Clc1cc(Cl)ncn1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N Oc1ccccc1Br Chemical compound Oc1ccccc1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
| US14/056,560 | 2013-10-17 | ||
| PCT/US2014/061033 WO2015058031A1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533366A JP2016533366A (ja) | 2016-10-27 |
| JP2016533366A5 JP2016533366A5 (enExample) | 2017-11-24 |
| JP6374959B2 true JP6374959B2 (ja) | 2018-08-15 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523925A Active JP6374959B2 (ja) | 2013-10-17 | 2014-10-17 | Ｄｎａ−ｐｋ阻害剤 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (enExample) |
| JP (1) | JP6374959B2 (enExample) |
| CN (1) | CN105636958B (enExample) |
| AU (1) | AU2014337208B2 (enExample) |
| BR (1) | BR112016008423B1 (enExample) |
| CA (1) | CA2927392C (enExample) |
| DK (1) | DK3057959T3 (enExample) |
| ES (1) | ES2671354T3 (enExample) |
| HR (1) | HRP20180804T1 (enExample) |
| HU (1) | HUE037516T2 (enExample) |
| LT (1) | LT3057959T (enExample) |
| PL (1) | PL3057959T3 (enExample) |
| PT (1) | PT3057959T (enExample) |
| RS (1) | RS57306B1 (enExample) |
| SI (1) | SI3057959T1 (enExample) |
| TR (1) | TR201807411T4 (enExample) |
| WO (1) | WO2015058031A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013186159A1 (en) | 2012-06-13 | 2013-12-19 | F. Hoffmann-La Roche Ag | New diazaspirocycloalkane and azaspirocycloalkane |
| HRP20191937T1 (hr) | 2012-09-25 | 2020-01-10 | F. Hoffmann - La Roche Ag | Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| RS56776B1 (sr) | 2013-11-26 | 2018-04-30 | Hoffmann La Roche | Derivati oktahidro-ciklobuta [1,2-c;3,4-c']dipirola kao inhibitori autotaksina |
| UA118582C2 (uk) | 2014-03-26 | 2019-02-11 | Ф. Хоффманн-Ля Рош Аг | Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa) |
| CA2935612A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CR20180058A (es) | 2015-09-04 | 2018-02-26 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| EP3353176B1 (en) | 2015-09-24 | 2022-01-19 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| PE20180552A1 (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca |
| EP3353180B1 (en) | 2015-09-24 | 2022-03-16 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| MX394860B (es) * | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| BR112019019017A2 (pt) | 2017-03-16 | 2020-04-14 | Hoffmann La Roche | compostos heterocíclicos de utilidade como inibidores duplos de atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| ES2893452T3 (es) * | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| EP3625223B1 (en) * | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| DK3625224T3 (da) | 2017-05-18 | 2021-11-08 | Idorsia Pharmaceuticals Ltd | N-substituerede indolderivater |
| ES2887041T3 (es) * | 2017-05-18 | 2021-12-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| EP3717475B1 (en) | 2017-11-20 | 2023-06-07 | Icahn School of Medicine at Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| WO2019143675A1 (en) | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| JP7483612B2 (ja) | 2018-01-17 | 2024-05-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| AU2019418800A1 (en) * | 2018-12-31 | 2021-07-01 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| EP4086258A4 (en) * | 2019-12-31 | 2023-11-29 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Purine derivative and medical use thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| WO2005026129A1 (en) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US20090221581A1 (en) * | 2005-05-25 | 2009-09-03 | Philipp Wabnitz | Methods of treating pain |
| MX2009003456A (es) * | 2006-10-02 | 2009-04-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteina cinasa. |
| US8518948B2 (en) * | 2010-03-10 | 2013-08-27 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| SI3459942T1 (sl) * | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
-
2014
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en not_active Ceased
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 HR HRP20180804TT patent/HRP20180804T1/hr unknown
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3057959T3 (pl) | 2018-08-31 |
| AU2014337208B2 (en) | 2018-05-24 |
| RS57306B1 (sr) | 2018-08-31 |
| JP2016533366A (ja) | 2016-10-27 |
| CA2927392A1 (en) | 2015-04-23 |
| EP3057959B1 (en) | 2018-02-28 |
| CA2927392C (en) | 2021-11-09 |
| CN105636958A (zh) | 2016-06-01 |
| WO2015058031A1 (en) | 2015-04-23 |
| TR201807411T4 (tr) | 2018-06-21 |
| BR112016008423B1 (pt) | 2022-02-22 |
| BR112016008423A2 (enExample) | 2017-08-01 |
| LT3057959T (lt) | 2018-06-11 |
| DK3057959T3 (en) | 2018-06-06 |
| ES2671354T3 (es) | 2018-06-06 |
| PT3057959T (pt) | 2018-06-04 |
| HUE037516T2 (hu) | 2018-09-28 |
| HRP20180804T1 (hr) | 2018-08-10 |
| CN105636958B (zh) | 2018-01-05 |
| SI3057959T1 (en) | 2018-07-31 |
| EP3057959A1 (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6741825B2 (ja) | Ｄｎａ−ｐｋ阻害剤 | |
| JP6374959B2 (ja) | Ｄｎａ−ｐｋ阻害剤 | |
| AU2014337208A1 (en) | DNA-PK inhibitors | |
| HK40003569A (en) | Dna-pk inhibitors | |
| HK40003569B (en) | Dna-pk inhibitors | |
| HK1207859B (en) | Dna-pk inhibitors | |
| HK1208022B (en) | Dna-pk inhibitors | |
| HK1228386B (en) | Dna-pk inhibitors | |
| HK1228386A1 (en) | Dna-pk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171016 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180622 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180628 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180720 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6374959 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |